+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Depot Typical Antipsychotics versus Oral Atypical Antipsychotics in Relapse Rate Among Patients with Schizophrenia: A Five -Year Historical Cohort Study



Depot Typical Antipsychotics versus Oral Atypical Antipsychotics in Relapse Rate Among Patients with Schizophrenia: A Five -Year Historical Cohort Study



Iranian Journal of Psychiatry and Behavioral Sciences 8(1): 66-71



The present study aimed to review the relapse rate in patients with schizophrenia treated with orally taken atypical agents (serotonin dopamine antagonists, SDAs) and depot preparation of conventional (typical) antipsychotics. In this historical cohort study, mean relapse per month (MRM) index, duration between initiation of antipsychotic treatment and the first relapse episode, and the time gap between successive relapses were compared between 84 patients on SDAs-except clozapine (group 1) and 81 others on depot typical antipsychotics (group 2). The two groups were comparable regarding mean (±SD) MRM index [0.033 (±0.004) in group1 and 0.044 (±0.05) in group 2; p = 0.345]. Mean (±SD) duration of time between initiation of maintenance treatment and the first relapse was 15.5 (±13.67) months in group 1 and 16.40 (±15.31) months in group 2, (p = 0.876). Mean (±SD) duration of remission periods between successive relapses were 17.92 (±14.2) and 15.8 (±16.9) months for group 1 and group 2, respectively (Mann-Whitney test, (p = 0.048). Orally taken atypical antipsychotics were able to keep the duration of remission periods between successive relapses more prolonged compared to depot conventional preparations. This could be added to their other remarkable benefits especially if the patient is expected to experience multiple relapses. None.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052492242

Download citation: RISBibTeXText

PMID: 24995032


Related references

Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics. Psychiatrische Praxis 34(6): 289-291, 2007

Readmission Rates of Patients with Schizophrenia Treated with Depot Antipsychotics versus Oral Antipsychotics in a Community Hospital. Cureus 10(12): E3775, 2019

Depot antipsychotics may reduce risk of relapse compared with oral antipsychotics in people with schizophrenia. 2011

Perceptions on efficacy and side effects of conventional depot antipsychotics (CDA) and atypical depot antipsychotics (ADA): Psychiatrists versus patients in Hong Kong. International Journal of Psychiatry in Clinical Practice 14(1): 23-32, 2010

Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics. Psychiatry and Clinical Neurosciences 58(3): 268-273, 2004

Characteristics and Use Patterns of Patients Taking First-Generation Depot Antipsychotics or Oral Antipsychotics for Schizophrenia. Psychiatric Services 58(4): 482-488, 2007

Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatric Services 58(4): 482-488, 2007

Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia. Human Psychopharmacology 28(5): 438-446, 2014

Atypical antipsychotics not associated with improved hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice. Evidence-Based Mental Health 16(2): 36, 2013

Comparing the efficacy of long-acting pharmaceutical forms (depot) versus oral pharmaceutical forms of atypical and conventional antipsychotics used in Spain for treating patients with schizophrenia. Revista de Psiquiatria Y Salud Mental 2(1): 5-28, 2009

Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use. Journal of Clinical Psychopharmacology 28(2): 125-131, 2008

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. American Journal of Psychiatry 168(6): 603-609, 2011

A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia. Yearbook of Psychiatry and Applied Mental Health 2013: 368-369, 2013

Relapse with oral antipsychotics versus long-acting injectable antipsychotics: new paradoxical findings. Evidence-Based Mental Health 17(3): 84, 2015

Do atypical antipsychotics really enhance smoking reduction more than typical ones?: the effects of antipsychotics on smoking reduction in patients with schizophrenia. Journal of Clinical Psychopharmacology 33(3): 319-328, 2013